Gastroesophageal cancer

Summary

Gastroesophageal cancer (MONDO:0850129) is a cancer and 102 clinical trials. Top therapeutic interventions include ramucirumab, relatlimab, and abemaciclib. A subtype of digestive system cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 102

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	gastroesophageal cancer
Mondo ID	MONDO:0850129
DOID	DOID:0080374
UMLS	C0346619
MedGen	577508
Is cancer (heuristic)	yes

Disease family

This is a subtype of digestive system cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › gastroesophageal cancer

Related subtypes (14): gastric cancer, jaw cancer, liver cancer, gastrointestinal lymphoma, gallbladder cancer, oral cavity cancer, pharynx cancer, intestinal cancer, spleen cancer, digestive system carcinoma, esophageal cancer, malignant pancreatic neoplasm, malignant tumor of floor of mouth, digestive system melanoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 102.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	38
Not specified	26
PHASE1	21
PHASE1/PHASE2	10
PHASE3	5
PHASE4	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06963593	PHASE4	NOT_YET_RECRUITING	Clinical Study on the Treatment of Anorexia and Cachexia in Advanced Gastric and Esophageal Cancer With Nanosized Megestrol Acetate Combined With Immunochemotherapy
NCT06028737	PHASE2/PHASE3	RECRUITING	Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer
NCT06356311	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
NCT00718354	PHASE3	COMPLETED	Overall Survival of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy(CT) vs Standard CT
NCT02853474	PHASE3	COMPLETED	Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy
NCT03013010	PHASE3	COMPLETED	PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy
NCT03813784	PHASE3	COMPLETED	A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
NCT03610711	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
NCT04069273	PHASE2	RECRUITING	Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
NCT04164979	PHASE2	ACTIVE_NOT_RECRUITING	Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma
NCT05379972	PHASE2	ACTIVE_NOT_RECRUITING	Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers
NCT05620134	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
NCT05632939	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.
NCT05965479	PHASE2	RECRUITING	Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer
NCT06109467	PHASE2	RECRUITING	Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
NCT06239194	PHASE1/PHASE2	RECRUITING	Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT06241469	PHASE2	NOT_YET_RECRUITING	Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study
NCT06422403	PHASE2	RECRUITING	A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
NCT06468280	PHASE2	RECRUITING	Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer
NCT06695845	PHASE2	RECRUITING	A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06906887	PHASE2	RECRUITING	PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer
NCT07477444	PHASE1/PHASE2	NOT_YET_RECRUITING	Perioperative Zanidatamab and Chemotherapy for HER2 Positive Gastroesophageal Cancer
NCT07529808	PHASE1/PHASE2	NOT_YET_RECRUITING	Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
NCT00080002	PHASE2	TERMINATED	Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction
NCT00256269	PHASE2	TERMINATED	Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma
NCT00525915	PHASE2	COMPLETED	Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma
NCT00673673	PHASE2	COMPLETED	FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
NCT01145404	PHASE2	TERMINATED	Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer
NCT01365130	PHASE2	TERMINATED	Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen
NCT01611857	PHASE1/PHASE2	COMPLETED	Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
NCT01715233	PHASE2	COMPLETED	Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.
NCT02274012	PHASE2	WITHDRAWN	Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment
NCT02317991	PHASE2	COMPLETED	Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer
NCT02669914	PHASE2	TERMINATED	MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
NCT02884453	PHASE2	UNKNOWN	Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma
NCT03165994	PHASE2	COMPLETED	APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers
NCT03314935	PHASE1/PHASE2	COMPLETED	A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
NCT03321630	PHASE2	COMPLETED	A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies
NCT03409848	PHASE2	COMPLETED	Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma
NCT03416244	PHASE2	COMPLETED	A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
RAMUCIRUMAB	4	2
RELATLIMAB	4	2
ABEMACICLIB	4	1
AFATINIB	4	1
AMIVANTAMAB	4	1
CABAZITAXEL	4	1
ENOXAPARIN SODIUM	4	1
FRUQUINTINIB	4	1
FUTIBATINIB	4	1
NERATINIB	4	1
TISLELIZUMAB	4	1
TRASTUZUMAB DERUXTECAN	4	1
ZANIDATAMAB	4	1
ZOLBETUXIMAB	4	1
CAMRELIZUMAB	3	2
RIVOCERANIB	3	2
BAVITUXIMAB	3	1
BEMARITUZUMAB	3	1
GEVOKIZUMAB	3	1
POTASSIUM	3	1
SACITUZUMAB TIRUMOTECAN	3	1
TIVANTINIB	3	1
TUSAMITAMAB RAVTANSINE	3	1
ZIMBERELIMAB	3	1
DKN-01	2	4
ETRUMADENANT	2	2
NAPTUMOMAB ESTAFENATOX	2	1
NUMIDARGISTAT	2	1
PEGAMOTECAN	2	1
SOTIGALIMAB	2	1